by referring both ppt and docx. frame questions that can be asked during presentation of our project along with answers
Reading File
Reading File
Browsing Directory
~/
Searching the Web
butterfly life cycle project presentation common questions answers
Browsing Directory
~/attachments/43e357f4-2144-4624-925a-dac0ea4879fa
Running Command
python3 -c "from pptx import Presentation; from docx import Document; ppt='/tmp/workspace/attachments/43e357f4-2144-4624-925a-dac0ea4879fa/pupa (1) (1).pptx'; docx='/tmp/workspace/attachments/43e357f4-2144-4624-925a-dac0ea4879fa/BUTTERFLY%20(wecompress.com).docx'; print('=== PPT ==='); prs=Presentation(ppt); print('slides:',len(prs.slides)); [print('\\n[SLIDE %d]\\n%s'%(i,'\\n'.join(s.text for s in sl.shapes if getattr(s,'has_text_frame',False) and s.text.strip()))) for i,sl in enumerate(prs.slides,1)]; print('\\n=== DOCX ==='); d=Document(docx); [print('[%s] %s'%(p.style.name,p.text)) for p in d.paragraphs if p.text.strip()]; [print('TABLE',ti, [[c.text for c in row.cells] for row in t.rows]) for ti,t in enumerate(d.tables,1)]"
Reading File
Finding Sources
Finding Sources
Searching PubMed
stroke pharmacist interventions
Likely presentation/viva questions with model answers
1. What is the main aim of your study?
Answer: The aim was to evaluate drug-utilization patterns in patients with cerebrovascular accident (CVA) and assess the role of clinical pharmacist interventions in identifying and resolving drug-related problems during hospitalization.
2. Why did you choose CVA patients for this study?
Answer: Stroke patients commonly have comorbidities such as hypertension, diabetes, cardiovascular disease, and seizures. They often receive multiple medicines, creating a high risk of polypharmacy, drug-drug interactions, adverse drug reactions, and medication errors. Therefore, they are an important group for Drug Utilization Evaluation, or DUE.
3. What is Drug Utilization Evaluation?
Answer: DUE is a systematic and structured review of medication use against predefined criteria. It evaluates whether drugs are selected, dosed, monitored, and used appropriately, safely, effectively, and economically.
4. What is the difference between DUE, DUR, and MUE?
Answer: These terms are often used interchangeably:
- DUE: Drug Utilization Evaluation
- DUR: Drug Utilization Review
- MUE: Medication Use Evaluation
All focus on evaluating medication-use patterns and improving rational use of medicines.
5. What was your study design?
Answer: It was a prospective observational study. We collected and reviewed data from eligible CVA inpatients during their hospitalization without assigning any treatment or changing therapy independently.
6. Why was a prospective observational design used?
Answer: A prospective design allowed systematic collection of patient demographics, diagnoses, prescribed drugs, doses, drug interactions, and pharmacist interventions while patients were admitted. Since it was observational, it reflects real-world prescribing practice.
7. Where was the study conducted?
Answer: The study was conducted among CVA inpatients admitted to the General Medicine Department and Emergency Ward of BMC&RC, Ballari.
8. What was your sample size?
Answer: We included 200 eligible CVA patients.
9. What were the inclusion criteria?
Answer: Patients were included if they:
- Were aged above 18 years
- Were diagnosed with CVA with or without comorbidities
- Were admitted to the emergency or general medicine ward
- Were willing to participate in the study
- Belonged to either sex
10. What were the exclusion criteria?
Answer: We excluded patients who:
- Did not consent to participate
- Had missing or insufficient data
- Were treated only in the outpatient department
- Were pediatric, pregnant, or psychiatric patients
11. What data did you collect?
Answer: We collected demographic data, stroke subtype, social history, comorbidities, past medical history, medication profile, dose and frequency, drug-drug interactions, polypharmacy, and pharmacist interventions.
12. What was the most common type of stroke in your study?
Answer: Ischemic stroke was the most common type, seen in 147 out of 200 patients, or 73.5%. Hemorrhagic stroke was seen in 21%, while TIA accounted for 5.5%.
13. Why was ischemic stroke more common than hemorrhagic stroke?
Answer: Ischemic stroke is generally the most common stroke subtype. It occurs because of arterial occlusion due to atherosclerosis, thrombus formation, or embolism. Common risk factors such as hypertension, diabetes, dyslipidemia, smoking, and atrial fibrillation contribute to its occurrence.
14. What was the gender distribution in your study?
Answer: Of the 200 patients, 125 were male, or 62.5%, and 75 were female, or 37.5%. Thus, male patients predominated in our sample.
15. Which age group was most commonly affected?
Answer: The 50-59 year age group was the most common, with 49 patients, or 24.5%. This was followed by the 60-69 year age group at 20.5%.
16. What was the most common comorbidity?
Answer: Hypertension was the most common comorbidity, accounting for 41.57% of recorded comorbidities. Diabetes mellitus was the next most common at 14.34%.
17. Why is hypertension important in stroke patients?
Answer: Hypertension is the leading modifiable risk factor for both ischemic and hemorrhagic stroke. It promotes vascular damage, atherosclerosis, small-vessel disease, and in severe cases can lead to vessel rupture and intracerebral hemorrhage.
18. What is polypharmacy?
Answer: Polypharmacy is commonly defined as the concurrent use of five or more medications by a patient.
19. What was the prevalence of polypharmacy in your study?
Answer: Polypharmacy was observed in 198 of 200 patients, which is 99%. This was expected because stroke inpatients often need acute management, treatment of comorbidities, prevention of recurrence, and supportive medications.
20. Is polypharmacy always irrational?
Answer: No. Polypharmacy may be clinically appropriate in patients with multiple comorbidities and acute illness. However, it must be regularly reviewed because it increases the risk of drug interactions, adverse drug reactions, medication errors, cost burden, and poor adherence after discharge.
21. Which drug classes were most frequently prescribed?
Answer: The most frequently prescribed classes were:
- Proton pump inhibitors: 94%
- Statins: 92.5%
- Osmotic diuretics: 62.5%
- Antihypertensives: 55%
- Antiemetics: 47.5%
- Antibiotics: 44%
- Single antiplatelet therapy: 43%
- Dual antiplatelet therapy: 35.5%
22. Why were statins prescribed in 92.5% of patients?
Answer: Statins, especially atorvastatin, are commonly used for secondary prevention in ischemic stroke. They lower LDL cholesterol and reduce future vascular events through lipid-lowering and plaque-stabilizing effects. Their use should be individualized according to stroke type, lipid profile, contraindications, and clinical status.
23. Why were antiplatelets frequently used?
Answer: Antiplatelets are used in non-cardioembolic ischemic stroke and TIA to reduce recurrent thrombotic events. Aspirin is commonly used as single antiplatelet therapy. Aspirin plus clopidogrel may be used for a short duration in selected patients with minor ischemic stroke or high-risk TIA.
24. Are antiplatelets appropriate in hemorrhagic stroke?
Answer: Not during the acute bleeding phase. In hemorrhagic stroke, the priority is blood-pressure control, reversal of anticoagulation when applicable, management of raised intracranial pressure, and neurosurgical assessment where required. Antiplatelet therapy should only be considered later after an individualized benefit-risk assessment.
25. Why was mannitol frequently prescribed?
Answer: Mannitol is an osmotic diuretic that may be used when cerebral edema or raised intracranial pressure is suspected, particularly in selected hemorrhagic stroke patients or patients with significant mass effect. It is not required routinely for every stroke patient and should be monitored for fluid balance, renal function, and electrolyte disturbances.
26. Why were PPIs prescribed to 94% of patients?
Answer: PPIs such as pantoprazole may be used for gastrointestinal protection, particularly in patients receiving antiplatelets, anticoagulants, corticosteroids, or multiple medications. However, a high rate of PPI use should be reviewed to ensure every prescription has a valid indication and duration.
27. What drug-related problems did you look for?
Answer: We looked for inappropriate drug selection, duplicate therapy, drug-drug interactions, inappropriate dose or frequency, untreated indications, adverse drug reactions, need for monitoring, and medication-use problems.
28. What were the common important drug interactions identified?
Answer: Important interactions included:
- Aspirin with clopidogrel, heparin, or acenocoumarol, which can increase bleeding risk
- Alteplase with antiplatelets, which can increase bleeding risk
- Carbamazepine with atorvastatin or clonazepam
- Furosemide with medicines affecting renal function or electrolytes
- Phenytoin with sodium valproate
- Nitroglycerin with labetalol, which may increase hypotension risk
The clinical relevance depends on patient condition, dose, timing, and monitoring.
29. Why is aspirin plus clopidogrel considered a potential interaction if both can be intentionally prescribed together?
Answer: The combination is not automatically inappropriate. It can be clinically indicated for a limited duration in selected patients with minor ischemic stroke or high-risk TIA. It is identified as an interaction because it increases bleeding risk and requires a clear indication, appropriate duration, and close monitoring.
30. What proportion of patients required pharmacist intervention?
Answer: Pharmacist intervention was provided for 158 of 200 patients, or 79%. Forty-two patients, or 21%, did not require a documented intervention.
31. What types of pharmacist interventions were performed?
Answer: The interventions included:
- Identifying drug-drug interactions
- Recommending dose, frequency, or duration adjustments
- Suggesting addition, substitution, or discontinuation of drugs where appropriate
- Monitoring for adverse drug reactions
- Reviewing medication appropriateness
- Providing patient counselling on medication adherence and lifestyle modification
32. How do pharmacist interventions benefit stroke patients?
Answer: Clinical pharmacists help detect medication-related problems early, support safer prescribing, monitor high-risk medicines, improve adherence, and educate patients about risk-factor control. This is especially relevant in stroke because many patients receive complex multi-drug regimens.
33. Can your study prove that pharmacist interventions improved clinical outcomes?
Answer: No. Our study supports the value of pharmacist involvement in identifying potential medication-related problems, but it cannot establish a direct cause-and-effect relationship with outcomes because it was observational, had no control group, and did not include long-term follow-up.
34. What are the major strengths of your study?
Answer: The strengths were:
- Prospective data collection during hospitalization
- Inclusion of 200 CVA patients
- Assessment of both prescribing patterns and pharmacist interventions
- Identification of polypharmacy and drug-drug interactions
- Generation of local baseline data that can support future quality-improvement initiatives
35. What are the limitations of your study?
Answer: The main limitations were:
- Single-center study, limiting generalizability
- Sample size of 200 patients
- No post-discharge follow-up for adherence, recurrence, mortality, or quality of life
- Observational design, so causality cannot be established
- Acceptance rate of pharmacist recommendations was not assessed
- Clinical outcomes of individual interventions were not measured
36. What is your main conclusion?
Answer: Ischemic stroke was the most common CVA subtype in our study. Hypertension was the most common comorbidity, and polypharmacy was highly prevalent. DUE helped identify prescribing patterns, potential drug interactions, and drug-related problems. Active clinical pharmacist involvement supported medication review, counselling, and optimization of therapy, thereby promoting safer and more rational medication use.
Questions an examiner may ask to test your critical appraisal
37. Your presentation states different interaction percentages in different places. Which result is correct?
Answer: This needs correction before the presentation. The Word document table reports 96 major, 64 moderate, 17 minor, and 30 with no interaction. However, the denominator is written as 209, although the study sample is 200, and these counts total 207. The PPT also gives different percentages. We will verify the original data sheet, use one correct denominator, and update all tables, figures, abstract, discussion, and slides consistently.
38. Why can the percentage of comorbidities be calculated using a denominator greater than 200?
Answer: A single patient can have more than one comorbidity. Therefore, the total number of recorded comorbidities can exceed the number of patients. We should clearly state that these are percentages of total comorbidity entries, not percentages of patients, to prevent misinterpretation.
39. Why do drug-class percentages add up to more than 100%?
Answer: Each patient may receive multiple drug classes, so the categories are not mutually exclusive. The percentages represent the proportion of patients exposed to each drug class, not portions of one total.
40. Why is the term “impact of pharmacist intervention” potentially too strong for this study?
Answer: “Impact” implies that clinical outcomes were measured and compared. Since this was an observational study without a control group or post-discharge follow-up, a more precise title would be: “A prospective observational study to assess drug utilization evaluation and clinical pharmacist interventions in CVA patients.”
41. What tool did you use to identify and grade drug-drug interactions?
Answer: We should name the exact interaction database or reference used and the criteria for classifying interactions as major, moderate, or minor. If this was not documented in the protocol, it should be clearly acknowledged as a methodological limitation and corrected before the viva.
42. How did you assess whether prescribed therapy was rational?
Answer: Therapy was assessed by reviewing indication, drug selection, dose, frequency, duration, contraindications, interactions, monitoring needs, and consistency with institutional or standard treatment guidance. Rational use does not mean every patient receives the same drugs. It means therapy is appropriate for the individual patient and clinical condition.
Important corrections to make before presenting
-
Correct the drug-interaction data.
Your PPT, abstract, discussion, and Word tables contain different percentages. The interaction table also uses N = 209, although your study population is 200, and the counts total 207. Verify the raw data and use one correct final result throughout. -
Correct the pharmacist-intervention table.
It states 42 patients had no intervention but shows 42%. This should be 21%, because 42/200 = 21%. -
Correct the diabetes comorbidity statement.
Your table reports 40 diabetes cases, corresponding to 14.34% of 279 comorbidity entries. One line incorrectly repeats 41.57%. -
Avoid saying all high PPI use was rational.
State that PPI use was common and may reflect gastroprotection needs, but should be reviewed for indication and duration. -
Avoid claiming improved patient outcomes unless measured.
Say: “Pharmacist interventions identified and addressed potential medication-related problems and supported medication safety.” Do not claim a confirmed reduction in mortality, recurrence, or hospital stay. -
Use “TIA,” not “transient stroke.”
The correct term is transient ischemic attack. -
Keep the clinical distinction clear.
Antiplatelets and anticoagulants are not routinely used in acute hemorrhagic stroke. Their use depends on stroke type and individual clinical indication.
A confident final line for the presentation is:
“Our study shows that hospitalized CVA patients have a high medication burden and substantial potential for drug-related problems. Routine DUE and active clinical pharmacist participation can strengthen medication review, patient counselling, and rational use of medicines in stroke care.”
different types of cross question by external
Reading File
Finding Sources
Finding Sources
Searching PubMed
stroke pharmacist intervention
Searching the Web
AHA ASA acute ischemic stroke guideline thrombolysis thrombectomy antiplatelet secondary prevention
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.